Skip to main content

Table 4 Disease flares in patients with and without PMR symptoms at diagnosis

From: Clinical outcomes of patients with giant cell arteritis treated with tocilizumab in real-world clinical practice: decreased incidence of new visual manifestations

  Patients with PMR symptoms at diagnosis (n = 32) Patients without PMR symptoms at diagnosis (n = 28)
Before TCZ initiation After TCZ initiation Before TCZ initiation After TCZ initiation
Follow-up time, median (IQR), years 0.7 (0.2–1.9) 0.6 (0.4–1.6) 0.6 (0.2–1.4) 0.5 (0.3–1.5)
Rate of flares per year*    1.6 (0.8–3.2)  
 Rate (95% CI) 1.3 (0.8–2.1) 0.5 (0.3–1.1)   0.7 (0.3–1.7)
 Rate ratio (95% CI)   0.4 (0.2–0.7)   0.4 (0.2–0.9)
p value   0.003   0.03
Patients with ≥ 1 flare, n (%) 24 (75.0) 11 (34.4) 19 (67.9) 7 (25.0)
 With PMR symptoms 21 (65.6) 8 (25.0) 4 (14.3) 2 (7.1)
 Without PMR symptoms 3 (9.4) 3 (9.4) 15 (53.6) 5 (17.9)
Total no. of flares 60 23 42 14
 With PMR symptoms, n (%) 50 (83.3) 18 (78.3) 7 (16.7) 3 (21.4)
 Without PMR symptoms, n (%) 10 (16.7) 5 (21.7) 35 (83.3) 11 (78.6)
  1. GCA giant cell arteritis, IQR interquartile range, PMR polymyalgia rheumatica, TCZ tocilizumab
  2. *Rates were estimated from a Poisson regression model with ongoing treatment (TCZ and glucocorticoid combinations), age, smoking history, and new or relapsing GCA as covariates, and random patient effect
  3. Symptoms were after GCA diagnosis. Percentage of flares is out of the total number of flares